FDA Brief

Warning letters Drugs

FDA warning letter to

COSMO KOREA

High riskIssued Nov 3, 2025Posted Nov 5, 2025Center for Drug Evaluation and Research (CDER)

FDA told South Korea's COSMO KOREA that its website sells unapproved, misbranded injectable botulinum toxin drugs to U.S. consumers.

What happened

FDA reviewed the company's website, www.cosmo-korea.com, rather than conducting an inspection. FDA found the site offering injectable botulinum toxin drug products for sale to U.S. consumers, including one marketed as "Nabota 200ui" and described with claims such as "blepharospasm elimination" and "hyperhidrosis elimination." FDA said these are unapproved new drugs and their labeling lacks adequate directions for use, which makes them misbranded.

What FDA found

  1. The company offers botulinum toxin type A as "Nabota 200ui" without any FDA-approved application for it.

    Sections 301(d) and 505(a) of the FD&C Act [21 U.S.C. §§ 331(d), 355(a)]
  2. Website claims that the product treats blepharospasm and hyperhidrosis show it is a drug intended for human use.

    21 CFR 201.128; section 201(g) of the FD&C Act [21 U.S.C. § 321(g)]
  3. The product's labeling does not give adequate directions for use, which is required for a drug.

    Section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)]
  4. Because it is a prescription drug for conditions a layperson cannot self-treat, safe directions cannot be written for consumers to use it on their own.

    Section 503(b)(1) of the FD&C Act [21 U.S.C. § 353(b)(1)]
  5. The product is not excused from the adequate-directions requirement because it is not approved in the U.S.

    21 CFR 201.115(a)
  6. By offering these drugs to U.S. consumers, the website causes misbranded drugs to enter interstate commerce.

    Section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]

What FDA wants

FDA asks the company to stop offering unapproved and misbranded drugs for sale to U.S. consumers and to review its websites, labels, and promotional materials. The company must reply in writing within 15 working days describing the steps taken and providing supporting documents.

Who should pay attention

  • U.S. clinics and med spas that buy injectables from overseas suppliers
  • distributors and importers of aesthetic injectable drugs
  • consumers who buy prescription cosmetic drugs from websites

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk